AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous frusemide
Number of subjects: 0
Study 6120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior oral metoprolol or propranolol
Number of subjects: 0
Study 6120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright tilting
Number of subjects: 0
Study 30636832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units over 2-4 hours (Group A)
Number of subjects: 271
Study 30636832 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 30 units over 8-12 hours (Group B)
Number of subjects: 271
Study 25911620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model group
Number of subjects: 1164
Study 24702815 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.4 U/kg therapeutic dose)
Number of subjects: 10
Study 24702815 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.8 U/kg high dose)
Number of subjects: 10
Study 24702815 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 10
Study 22439919 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAMPOLINE group programme (nine-session manualised intervention)
Number of subjects: 218
Study 22439919 — intervention group
Group type: COMPARATOR
Intervention: Control group programme (same duration, not addiction-specific)
Number of subjects: 218
Study 20356553 — intervention group
Group type: EXPERIMENTAL
Intervention: RPLS patients
Number of subjects: 20
Study 20356553 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal MRI findings)
Number of subjects: 20
Study 18626423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg (0.1 cc) of triamcinolone acetonide at the end of surgery
Number of subjects: 72
Study 18626423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 72
Study 16041723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cymbopogon nardus (citronella) undiluted oil
Number of subjects: 0
Study 16041723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pogostemon cablin (patchuli) undiluted oil
Number of subjects: 0
Study 16041723 — intervention group
Group type: EXPERIMENTAL
Intervention: Syzygium aromaticum (clove) undiluted oil
Number of subjects: 0
Study 16041723 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanthoxylum limonella (makaen) undiluted oil
Number of subjects: 0
Study 16041723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clove oil
Number of subjects: 0
Study 16041723 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% and 50% concentrations of tested oils
Number of subjects: 0
Study 12403927 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterbur extract (petasins)
Number of subjects: 0
Study 12403927 — intervention group
Group type: COMPARATOR
Intervention: Established antihistamine treatment
Number of subjects: 0
Study 9972747 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided transfusion algorithm
Number of subjects: 105
Study 9972747 — intervention group
Group type: COMPARATOR
Intervention: Routine transfusion therapy
Number of subjects: 105
Study 8788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABA receptor ligand) for 3 weeks
Number of subjects: 90
Study 8788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Sybazon preparation
Number of subjects: 90
Study 8788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 90
Study 8788983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2260157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (2 mg/hr constant intravenous infusion for 5 days, 120 mg/day orally for another 16 days)
Number of subjects: 23
Study 2260157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7430528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 8
Study 7430528 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 8
Study 7430528 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin + Pindolol
Number of subjects: 8
Study 7430528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7430528 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study 6355877 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive plasma exchanges (PE) plus conventional corticosteroid/azathioprine treatment
Number of subjects: 0
Study 6355877 — intervention group
Group type: COMPARATOR
Intervention: Conventional corticosteroid/azathioprine treatment
Number of subjects: 0
Study 31376748 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback weight shift training (WST) with active horizontal headshake (HS)
Number of subjects: 33
Study 31376748 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback weight shift training (WST) without HS (NoHS)
Number of subjects: 33
Study 31376748 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 33
Study 29063309 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (delivered face-to-face or by telephone)
Number of subjects: 337
Study 29063309 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 337
Study 27743448 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term weekly supragingival irrigations with aerosolized 0.5% hydrogen peroxide
Number of subjects: 43
Study 27743448 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival irrigation with aerosolized 0.5% hydrogen peroxide
Number of subjects: 43
Study 25373733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus Bevacizumab (15 mg/kg Bevacizumab and 1.3 mg/m2 Bortezomib)
Number of subjects: 91
Study 22674882 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium dinicocysteinate (CDNC)
Number of subjects: 100
Study 22674882 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CP)
Number of subjects: 100
Study 22674882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 100
Study 21677123 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA diet (17% energy from PUFA, 6.5% ALA)
Number of subjects: 20
Study 21677123 — intervention group
Group type: EXPERIMENTAL
Intervention: LA diet (16.4% energy from PUFA, 3.6% ALA)
Number of subjects: 20
Study 17510454 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 174
Study 17510454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 15704045 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 272
Study 15704045 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 272
Study 12036186 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees passive head up tilt (HUT) in patients with vitamin B12 deficiency
Number of subjects: 51
Study 12036186 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees passive head up tilt (HUT) in patients with diabetes mellitus
Number of subjects: 51
Study 12036186 — intervention group
Group type: COMPARATOR
Intervention: 60 degrees passive head up tilt (HUT) in healthy age‐matched control subjects
Number of subjects: 51
Study 10086212 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics team intervention
Number of subjects: 110
Study 7484032 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 1% mepivacaine (10 mg/ml)
Number of subjects: 80
Study 7484032 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of 1% mepivacaine (10 mg/ml)
Number of subjects: 80
Study 2245751 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft baby carriers (more physical contact)
Number of subjects: 49
Study 2245751 — intervention group
Group type: COMPARATOR
Intervention: Infant seats (less contact)
Number of subjects: 49
Study 7372262 — intervention group
Group type: EXPERIMENTAL
Intervention: Solugastril Gel (3 sachets daily)
Number of subjects: 20
Study 7372262 — intervention group
Group type: EXPERIMENTAL
Intervention: Solugastril Gel combined with Solu-Vetan
Number of subjects: 20
Study 31891694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 0
Study 30315625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine combined with sildenafil citrate (SC)
Number of subjects: 239
Study 30315625 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine alone
Number of subjects: 239
Study 30315625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine combined with SC
Number of subjects: 239
Study 28800989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal placement of 9-French Arndt bronchial blocker
Number of subjects: 41
Study 28800989 — intervention group
Group type: COMPARATOR
Intervention: Extraluminal placement of 9-French Arndt bronchial blocker
Number of subjects: 41
Study 28800989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intraluminal and Extraluminal)
Number of subjects: 41
Study 26308766 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG ASNase
Number of subjects: 990
Study 26308766 — intervention group
Group type: COMPARATOR
Intervention: Erwinia ASNase
Number of subjects: 990
Study 26308766 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive antibody titers postinduction
Number of subjects: 990
Study 26308766 — intervention group
Group type: COMPARATOR
Intervention: Negative antibody titers
Number of subjects: 990
Study 26308766 — intervention group
Group type: COMPARATOR
Intervention: Positive antibody titers
Number of subjects: 990
Study 26308766 — intervention group
Group type: COMPARATOR
Intervention: No ASNase postconsolidation
Number of subjects: 990
Study 23470315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 min treadmill run at approximately 70% of maximal oxygen uptake)
Number of subjects: 20
Study 23470315 — intervention group
Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 20
Study 23470315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study 20932656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) alone
Number of subjects: 20
Study 20932656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) plus radiotherapy (RT)
Number of subjects: 20
Study 18489224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory‐induced cold pressor pain
Number of subjects: 132
Study 18489224 — intervention group
Group type: COMPARATOR
Intervention: No pain condition
Number of subjects: 132
Study 16622270 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant (primary systemic) treatment for operable breast cancer
Number of subjects: 0
Study 16622270 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations from an international expert panel
Number of subjects: 0
Study 12930572 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human FSH (rhFSH) 75 IU FSH/ampoule, 150 IU total for the first 14 days
Number of subjects: 50
Study 12930572 — intervention group
Group type: COMPARATOR
Intervention: human menopausal gonadotrophin (HMG) 75 IU FSH and 75 IU LH/ampoule, 150 IU total for the first 14 days
Number of subjects: 50
Study 11001761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress in lean women
Number of subjects: 19
Study 11001761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress in obese women
Number of subjects: 19
Study 11001761 — intervention group
Group type: COMPARATOR
Intervention: Mental stress under propranolol in lean women
Number of subjects: 19
Study 9055522 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI)
Number of subjects: 74
Study 9055522 — intervention group
Group type: COMPARATOR
Intervention: Control (no history of TBI)
Number of subjects: 74
Study 8256886 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiorphan (2.5 mg/ml concentration, 0.5 ml nebulized dose)
Number of subjects: 8
Study 8256886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3552380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteric compression
Number of subjects: 0
Study 3552380 — intervention group
Group type: COMPARATOR
Intervention: No ureteric compression
Number of subjects: 0
Study 29514306 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent rotavirus vaccine
Number of subjects: 0
Study 29514306 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural immunity from prior RVD episodes
Number of subjects: 0
Study 29514306 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated cohorts with varying rotavirus incidence rates
Number of subjects: 0
Study 28647461 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (tIOL)
Number of subjects: 80
Study 28647461 — intervention group
Group type: COMPARATOR
Intervention: Peripheral corneal relaxing incisions (PCRI)
Number of subjects: 80
Study 28647461 — intervention group
Group type: COMPARATOR
Intervention: PCRI
Number of subjects: 80
Study 28647461 — intervention group
Group type: EXPERIMENTAL
Intervention: tIOL
Number of subjects: 80
Study 26329347 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/rosuvastatin fixed-dose combination (80/20 mg)
Number of subjects: 60
Study 26329347 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of telmisartan 80 mg and rosuvastatin 20 mg
Number of subjects: 60
Study 23897106 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBBCG (Bromocresol Green method)
Number of subjects: 44
Study 23897106 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBmBCP (Modified Bromocresol Purple method)
Number of subjects: 44
Study 20079396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (microradiography)
Number of subjects: 14
Study 20079396 — intervention group
Group type: COMPARATOR
Intervention: Group II (microCT)
Number of subjects: 14
Study 20467623 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants
Number of subjects: 60
Study 20467623 — intervention group
Group type: COMPARATOR
Intervention: Early loading of dental implants (6 weeks)
Number of subjects: 60
Study 16645293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nijmegen Falls Prevention Program (exercise group)
Number of subjects: 113
Study 16645293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 12580841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 mL injected into the uterus, fallopian tubes, and pelvis
Number of subjects: 78
Study 12580841 — intervention group
Group type: COMPARATOR
Intervention: Placebo normal saline 20 mL injected into the uterus, fallopian tubes, and pelvis
Number of subjects: 78
Study 11113041 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with low-dose weight-adjusted heparin
Number of subjects: 2792
Study 11113041 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with standard-dose weight-adjusted heparin
Number of subjects: 2792
Study 11113041 — intervention group
Group type: COMPARATOR
Intervention: placebo with standard-dose weight-adjusted heparin
Number of subjects: 2792
Study 8985725 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left heart valvular disease (Aortic regurgitation, Mitral regurgitation, Mixed aortic and mitral regurgitation)
Number of subjects: 55
Study 8985725 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left heart valvular disease
Number of subjects: 55
Study 1418046 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% flutrimazole skin cream
Number of subjects: 21
Study 1418046 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% flutrimazole skin cream
Number of subjects: 21
Study 1418046 — intervention group
Group type: EXPERIMENTAL
Intervention: Excipient only
Number of subjects: 21
Study 1418046 — intervention group
Group type: COMPARATOR
Intervention: 1% clotrimazole commercial skin cream
Number of subjects: 21
Study 1418046 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic tolerance testing
Number of subjects: 21
Study 3856293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2
Number of subjects: 4
Study 3856293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg PGE2
Number of subjects: 4
Study 3856293 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg PGE2
Number of subjects: 4
Study 3856293 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study 31138456 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (N=151)
Number of subjects: 307
Study 31138456 — intervention group
Group type: COMPARATOR
Intervention: Healthy education control (N=156)
Number of subjects: 307
Study 31138456 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 307
Study 30082027 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 100
Study 30082027 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert feedback
Number of subjects: 100
Study 30082027 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 100
Study 27348915 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-pricking therapy at Guanyuan (CV 4) and bilateral sacral plexus nerve, lumbar 1 nerve and greater occipital nerve stimulating points, once a week for 9 weeks
Number of subjects: 36
Study 27348915 — intervention group
Group type: COMPARATOR
Intervention: Midodrine tablets prescribed orally, three times a day for 9 weeks
Number of subjects: 36
Study 24721240 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine Liuweiwuling tablets in combination with entecavir
Number of subjects: 430
Study 24721240 — intervention group
Group type: COMPARATOR
Intervention: Entecavir alone (control group)
Number of subjects: 430
Study 22493375 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIRI
Number of subjects: 74
Study 22493375 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 74
Study 20472604 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive then negative information
Number of subjects: 84
Study 20472604 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative then positive information
Number of subjects: 84
Study 20472604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 18191102 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical significance tests used in RCTs
Number of subjects: 193
Study 18191102 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of clinical significance
Number of subjects: 193
Study 18191102 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of statistical power
Number of subjects: 193
Study 18191102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of effect size
Number of subjects: 193
Study 18191102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of confidence intervals
Number of subjects: 193
Study 18191102 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of knowing magnitude and clinical importance of effect
Number of subjects: 193
Study 15894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 506
Study 15894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Past smokers
Number of subjects: 506
Study 15894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking > or =2 packs/d
Number of subjects: 506
Study 15894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking for > or =11 years
Number of subjects: 506
Study 15894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater smoking intensity
Number of subjects: 506
Study 15894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater smoking duration
Number of subjects: 506
Study 12519332 — intervention group
Group type: EXPERIMENTAL
Intervention: New collagen barrier (Ossix)
Number of subjects: 28
Study 12519332 — intervention group
Group type: COMPARATOR
Intervention: Standard e-PTFE membrane (Gore-Tex)
Number of subjects: 28
Study 10364995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide 20 ppm
Number of subjects: 60
Study 10364995 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen (control)
Number of subjects: 60
Study 7990859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 408
Study 7990859 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 408
Study 7990859 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron + Dexamethasone
Number of subjects: 408
Study 1283552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 0
Study 1283552 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered intermittent intramuscular (IM) injections of morphine
Number of subjects: 0
Study 3004550 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculous chemotherapy (2-week course)
Number of subjects: 41
Study 3004550 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculous chemotherapy including rifampicin
Number of subjects: 41
Study 3004550 — intervention group
Group type: COMPARATOR
Intervention: Antituberculous chemotherapy without rifampicin
Number of subjects: 41
Study 31295009 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmailong injection (100 mg/2 mL, intravenous drip infusion)
Number of subjects: 100
Study 31295009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal amounts of XI placebo)
Number of subjects: 100
Study 31295009 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus XI
Number of subjects: 100
Study 29668900 — intervention group
Group type: EXPERIMENTAL
Intervention: HCoV ARI incidence in infants
Number of subjects: 3505
Study 29668900 — intervention group
Group type: EXPERIMENTAL
Intervention: HCoV incidence rate
Number of subjects: 3505
Study 29668900 — intervention group
Group type: EXPERIMENTAL
Intervention: HCoV incidence in nonneonates vs neonates
Number of subjects: 3505
Study 29668900 — intervention group
Group type: EXPERIMENTAL
Intervention: HCoV ARI incidence related to household factors
Number of subjects: 3505
Study 29668900 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfections with other respiratory viruses
Number of subjects: 3505
Study 29668900 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variation of HCoV
Number of subjects: 3505
Study 26346590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity maintenance programme (2-hour sessions at 3, 6, and 9 months)
Number of subjects: 148